GlaxoSmithKline Stock – Hikma Pharmaceuticals Resumes US Launch of Generic of GSK Asthma Treatment
By Anthony O. Goriainoff
Hikma Pharmaceuticals PLC said Wednesday that it has resumed the launch of its generic version of GlaxoSmithKline PLC’s asthma treatment, Advair Diskus, in the U.S.
The FTSE 100 pharmaceutical company said the move followed the Food and Drug Administration’s approval of the amendment to its abbreviated new drug application, submitted in January. The change reflected enhanced packaging controls required to meet industry standards adopted since the time of the initial submission.
Write to Anthony O. Goriainoff at [email protected]
(END) Dow Jones Newswires